|
Net sales
|
|
$340.1m
|
$321.2m
|
$430.9m
|
$512.1m
|
$512.3m
|
$573.3m
|
$568.1m
|
|
Cost of sales (including depreciation and amortization of $41,251, $41,882 and $48,503, respectively)
|
|
$90.9m
|
$87.6m
|
$128.2m
|
$181.0m
|
$184.2m
|
$185.1m
|
$179.9m
|
|
Gross profit
|
|
$249.2m
|
$233.5m
|
$302.7m
|
$331.1m
|
$328.2m
|
$388.2m
|
$388.2m
|
|
Operating income (loss)
|
|
$31.2m
|
$21.2m
|
$12.1m
|
($251.0m)
|
($81.7m)
|
($12.0m)
|
$54.0m
|
|
Change in fair value of contingent consideration
|
|
$0
|
$0
|
$829k
|
$6.5m
|
$719k
|
$1.4m
|
$0
|
|
Depreciation and amortization
|
|
$7.9m
|
$7.4m
|
$8.4m
|
$21.2m
|
$8.8m
|
$7.7m
|
$5.7m
|
|
Impairment of assets
|
|
—
|
—
|
$0
|
$0
|
$78.6m
|
$36.4m
|
$0
|
|
Loss on disposals
|
|
—
|
—
|
$0
|
$0
|
$3.6m
|
$292k
|
$81k
|
|
Loss on extinguishment
|
|
—
|
—
|
—
|
—
|
$0
|
$0
|
$326k
|
|
Income (loss) before income taxes
|
|
$9.7m
|
$15.9m
|
$7.6m
|
($263.9m)
|
($121.1m)
|
($49.1m)
|
$25.7m
|
|
Net income (loss) from continuing operations
|
|
$8.1m
|
$14.7m
|
$9.6m
|
($144.7m)
|
($121.2m)
|
($43.8m)
|
$27.3m
|
|
Loss from discontinued operations, net of tax
|
|
$1.8m
|
$0
|
$0
|
($68.7m)
|
($74.4m)
|
$0
|
$0
|
|
(Income) loss attributable to noncontrolling interest - continuing operations
|
|
—
|
—
|
$9.8m
|
$40.7m
|
$24.5m
|
$10.3m
|
($4.5m)
|
|
Loss attributable to noncontrolling interest - discontinued operations
|
|
—
|
—
|
$0
|
$14.0m
|
$14.9m
|
$0
|
$0
|
|
Change in foreign currency translation adjustments
|
|
($322k)
|
$2.1m
|
($1.3m)
|
($501k)
|
$1.1m
|
($4.2m)
|
$1.8m
|
|
Change in the fair value of cash flow hedges
|
|
—
|
—
|
—
|
—
|
$0
|
$0
|
($991k)
|
|
Comprehensive income (loss)
|
|
$5.9m
|
$16.8m
|
$8.3m
|
($213.8m)
|
($194.5m)
|
($48.0m)
|
$28.1m
|
|
Comprehensive (income) loss attributable to noncontrolling interest - continuing operations
|
|
—
|
—
|
$9.8m
|
$40.8m
|
$24.2m
|
$11.1m
|
($4.7m)
|
|
Comprehensive loss attributable to noncontrolling interest - discontinued operations
|
|
—
|
—
|
$0
|
$14.0m
|
$14.9m
|
$0
|
$0
|
|
Comprehensive income (loss) attributable to Bioventus Inc.
|
|
$6.5m
|
$18.5m
|
$18.1m
|
($159.0m)
|
($155.3m)
|
($36.9m)
|
$23.4m
|
|
Basic (in shares)
|
|
—
|
—
|
$45.5m
|
$61.4m
|
$62.6m
|
$64.5m
|
$66.6m
|
|
Diluted (in shares)
|
|
—
|
—
|
$45.5m
|
$61.4m
|
$62.6m
|
$64.5m
|
$68.9m
|
|
Net income (loss)
|
|
$6.3m
|
$14.7m
|
$9.6m
|
($213.4m)
|
($195.6m)
|
($43.8m)
|
$27.3m
|
|
Net income (loss) attributable to Bioventus Inc.
|
|
$6.9m
|
$16.4m
|
$19.4m
|
($158.7m)
|
($156.2m)
|
($33.5m)
|
$22.7m
|
|
Continuing operations, basic (in dollars per share)
|
|
—
|
—
|
($0.11)
|
($1.70)
|
($1.54)
|
($0.52)
|
$0.34
|
|
Discontinued operations, basic (in dollars per share)
|
|
—
|
—
|
($0.04)
|
($0.89)
|
($0.95)
|
$0.00
|
$0.00
|
|
Basic income (loss) per Class A common stock (in dollars per share)
|
|
—
|
—
|
($0.15)
|
($2.59)
|
($2.49)
|
($0.52)
|
$0.34
|
|
Continuing operations, diluted (in dollars per share)
|
|
—
|
—
|
($0.11)
|
($1.70)
|
($1.54)
|
($0.52)
|
$0.33
|
|
Discontinued operations, diluted (in dollars per share)
|
|
—
|
—
|
($0.04)
|
($0.89)
|
($0.95)
|
$0.00
|
$0.00
|
|
Diluted income (loss) per Class A common stock (in dollars per share)
|
|
—
|
—
|
($0.15)
|
($2.59)
|
($2.49)
|
($0.52)
|
$0.33
|
|
Selling, general and administrative expense
|
|
$198.5m
|
$193.1m
|
$254.3m
|
$332.6m
|
$303.9m
|
$340.9m
|
$314.0m
|
|
Research and development expense
|
|
$11.1m
|
$11.2m
|
$19.0m
|
$25.9m
|
$13.4m
|
$13.6m
|
$12.1m
|
|
Restructuring costs
|
|
$575k
|
$563k
|
$2.5m
|
$6.8m
|
$840k
|
($52k)
|
$2.2m
|
|
Interest expense, net
|
|
$21.6m
|
$9.8m
|
$1.1m
|
$25.8m
|
$40.7m
|
$38.8m
|
$26.5m
|
|
Other expense (income)
|
|
$21.5m
|
$5.3m
|
$4.4m
|
$12.9m
|
$39.4m
|
$37.1m
|
$28.3m
|
|
Income tax (benefit) expense, net
|
|
$1.6m
|
$1.2m
|
($2.0m)
|
($50.5m)
|
$85k
|
($5.3m)
|
($1.6m)
|
|
Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment
|
|
($78k)
|
($54k)
|
$60k
|
$133k
|
($8k)
|
$13k
|
$21k
|